ICML 2019 | Adding acalabrutinib to the arsenal: impact of ASCEND in CLL

Barbara Eichhorst

Barbara Eichhorst, MD, University Hospital of Cologne, Cologne, Germany, discusses the ASCEND trial (NCT02970318) of acalabrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL), and the potential impact of the results on clinical practice. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video